FutureLife, a leading pan-European provider of IVF and genetic services, has made a strategic move in expanding its presence in Romania by acquiring Gynatal, a well-established fertility clinic in Timisoara. This acquisition complements FutureLife’s previous purchases of Gynera, a top fertility clinic in Bucharest, and the Cytogenomic Medical Laboratory, which offers advanced clinical and molecular genetics services in the capital. The company now operates a robust network across Romania, solidifying its position in a market with considerable growth potential.
Gynatal, founded in 2004 and accredited for IVF in 2009, is known for its comprehensive fertility services and its long-standing expertise in embryology. The clinic offers both private and publicly-funded IVF treatments, ensuring access to fertility care for a diverse range of patients. It has earned a solid reputation for its clinical excellence and personalized care, and its acquisition by FutureLife will enable the group to strengthen its offerings across Romania.
“We are excited to welcome Gynatal into the FutureLife family. With its strong reputation for clinical excellence, Gynatal is a perfect fit for our expanding network in Romania. This acquisition, alongside our earlier purchase of Gynera, helps us offer world-class reproductive services to more patients across both major regions, whether through private or public funding,” said Francisco Lobbosco, CEO of FutureLife.
Lobbosco also emphasized the importance of GNT Lab, one of Europe’s most advanced genetic laboratories, in supporting FutureLife’s ability to meet the growing demand for genetic services, including prenatal screening. “Our strategy continues to focus on harmonizing best practices across all FutureLife clinics, while preserving the local expertise that makes each clinic unique. With Gynatal’s deep knowledge of patient needs in Timisoara and our global resources, we are confident in our ability to deliver exceptional outcomes,” he added.
The acquisition of Gynatal also represents a major step for the clinic itself. “Joining FutureLife gives us the opportunity to expand our capabilities and serve even more patients. With the support of FutureLife, we can continue to provide exceptional fertility care both privately and through Ministry of Family-supported programs,” said Dr. Florin Dorneanu, Medical Director of Gynatal.
In an interview with Business Review, Lobbosco discussed the evolving fertility landscape in Romania and the opportunities the country presents for FutureLife’s growth. “Since 2009, we have focused on acquiring and integrating high-performing clinics in Romania, starting with Gynera in 2019, followed by the Cytogenomic Medical Laboratory in 2022. The addition of Gynatal in 2024 marks another strategic milestone in our expansion,” he explained.
While there are clear challenges in Romania’s fertility market, including limited public awareness and financial barriers to accessing IVF treatments, the opportunities are significant. “Many patients struggle with access to advanced fertility care, either due to cost or the scarcity of clinics in certain regions. Public programs, like those supported by the Ministry of Family, also require ongoing adaptation to changing regulations,” Lobbosco noted.
However, as awareness of fertility issues grows and reproductive medicine evolves, FutureLife is well-positioned to meet this demand. “As more patients seek specialized care, we aim to offer cutting-edge technologies like those provided by GNT Lab to deliver the highest quality fertility services,” Lobbosco added. The public programs that subsidize fertility treatments in Romania further enhance the accessibility of services, enabling FutureLife to support a wider range of patients.
With the Romanian fertility market expanding, FutureLife’s combination of local expertise and international resources positions the company for continued success and growth in the region.
Related topics:
